The marketing authorisation application (MAA) for Nidlegy was submitted in June 2024, but Philogen decided to withdraw it due to delays in the availability of Chemistry, Manufacturing and Controls (CMC) data and additional clinical information.
The marketing authorisation application (MAA) for Nidlegy was submitted in June 2024, but Philogen decided to withdraw it due to delays in the availability of Chemistry, Manufacturing and Controls (CMC) data and additional clinical information.